scholarly journals Using γ-Camera to Evaluate the In Vivo Biodistributions and Internal Medical Dosimetries of Iodine-131 in Thyroidectomy Patients

Author(s):  
Sheng-Pin Changlai ◽  
Tom Changlai ◽  
Chien-Yi Che
Keyword(s):  
Nature ◽  
1963 ◽  
Vol 198 (4876) ◽  
pp. 169-170 ◽  
Author(s):  
NOBORU YAMAGATA ◽  
KIYOSHI IWASHIMA

2005 ◽  
Vol 11 (20) ◽  
pp. 7288-7296 ◽  
Author(s):  
Ingrid Burvenich ◽  
Steve Schoonooghe ◽  
Bart Cornelissen ◽  
Peter Blanckaert ◽  
Elisabeth Coene ◽  
...  

1976 ◽  
Vol 27 (10) ◽  
pp. 539-545 ◽  
Author(s):  
Phillip Plato ◽  
A.P. Jacobson ◽  
Steven Homann
Keyword(s):  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4512-4512
Author(s):  
Rongcheng Luo ◽  
Qiang Zuo ◽  
Li Wei ◽  
Wangjun Liang ◽  
Dayong Zhen ◽  
...  

Abstract The purpose of this study was to investigate the cell specific cytotoxic effect of Iodine-131 Rituximab on CD20-positive B cell lymphoma in vitro and on Raji cell tumors grown in vivo. Rituximab was labeled with Iodine -131 by the iodogen method. Cultured Raji cells or the nude mice bearing Raji tumors were treated with various concentrations of Iodine-131-Rituximab or Iodine-131 alone or Rituximab alone. The results showed that The lethal effect was found on Raji cells treated with Iodine-131-Rituximab in a dose-dependent manner; The proliferation rate of Raji cells was significantly lower in cells treated with Iodine-131-Rituximab, as compared to the cells treated with Iodine-131or Rituximab alone (P<0.05); Tumor inhibition was found to be greatest in the mice treated with Iodine-131-Rituximab through intratumor injection, as compared with Iodine-131-Rituximab i.p. injection or Rituximab alone (p<0.05). We conclude that Iodine-131-Rituximab specifically inhibits the growth of Raji tumor cells in vitro and in vivo. Iodine-131-Rituximab is a promising agent for radioimmunotherapy that targets CD20-positive B cell lymphoma.


1963 ◽  
Vol 9 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Gerard R. Laurer ◽  
Merril Eisenbud

2016 ◽  
Vol 113 ◽  
pp. 1-4 ◽  
Author(s):  
B.M. Dantas ◽  
F.F. Lima ◽  
A.L. Dantas ◽  
E.A. Lucena ◽  
R.M.G. Gontijo ◽  
...  

2013 ◽  
Vol 15 (10) ◽  
Author(s):  
Uğur Avcıbaşı ◽  
Nesibe Avcıbaşı ◽  
Hilmi Arkut Akalın ◽  
Melis Ediz ◽  
Hasan Demiroğlu ◽  
...  
Keyword(s):  

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Yingying Zhang ◽  
Yongxue Zhang ◽  
Lianglan Yin ◽  
Xiaotian Xia ◽  
Fan Hu ◽  
...  

Introduction.Radiolabeled gold nanoparticles play an important role in biomedical application. The aim of this study was to prepare iodine-131 (131I)-labeled gold nanorods (GNRs) conjugated with cyclic RGD and evaluate its biological characteristics for targeted imaging of integrinαvβ3-expressing tumors.Methods.HS-PEG(5000)-COOH molecules were applied to replace CTAB covering the surface of bare GNRs for better biocompatibility, and c(RGDfK) peptides were conjugated onto the carboxyl terminal of GNR-PEG-COOH via EDC/NHS coupling reactions. The nanoconjugate was characterized, and131I was directly tagged on the surface of GNRs via AuI bonds for SPECT/CT imaging. We preliminarily studied the characteristics of the probe and its feasibility for tumor-targeting SPECT/CT imaging.Results.The[131I]GNR-PEG-cRGD probe was prepared in a simple and rapid manner and was stable in both PBS and fetal bovine serum. It targeted selectively and could be taken up by tumor cells mainly via integrinαvβ3-receptor-mediated endocytosis. In vivo imaging, biodistribution, and autoradiography results showed evident tumor uptake in integrinαvβ3-expressing tumors.Conclusions.These promising results showed that this smart nanoprobe can be used for angiogenesis-targeted SPECT/CT imaging. Furthermore, the nanoprobe possesses a remarkable capacity for highly efficient photothermal conversion in the near-infrared region, suggesting its potential as a multifunctional theranostic agent.


Sign in / Sign up

Export Citation Format

Share Document